Disc Medicine (NASDAQ:IRON) Upgraded at Morgan Stanley

Morgan Stanley upgraded shares of Disc Medicine (NASDAQ:IRON - Free Report) from an equal weight rating to an overweight rating in a research note released on Tuesday, MarketBeat reports. They currently have $85.00 price objective on the stock.

IRON has been the subject of a number of other research reports. Scotiabank began coverage on Disc Medicine in a research report on Wednesday, October 16th. They issued a "sector outperform" rating and a $62.00 price target for the company. Jefferies Financial Group assumed coverage on shares of Disc Medicine in a research report on Wednesday, October 23rd. They issued a "buy" rating and a $89.00 price target on the stock. Wells Fargo & Company began coverage on Disc Medicine in a research report on Thursday, August 22nd. They set an "overweight" rating and a $75.00 price objective on the stock. Cantor Fitzgerald reissued an "overweight" rating and issued a $85.00 target price on shares of Disc Medicine in a report on Tuesday, October 15th. Finally, HC Wainwright restated a "buy" rating and issued a $70.00 price target on shares of Disc Medicine in a research report on Monday, October 28th. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $79.40.

Disc Medicine Stock Up 10.1 %

Shares of IRON traded up $5.86 during trading hours on Tuesday, reaching $64.11. The company's stock had a trading volume of 700,297 shares, compared to its average volume of 354,120. The firm has a market cap of $1.91 billion, a price-to-earnings ratio of -17.43 and a beta of 0.60. The company has a 50 day moving average of $48.75 and a two-hundred day moving average of $42.93. Disc Medicine has a 1-year low of $25.60 and a 1-year high of $77.60.

Disc Medicine (NASDAQ:IRON - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($1.03) EPS for the quarter, beating the consensus estimate of ($1.11) by $0.08. As a group, analysts forecast that Disc Medicine will post -4.09 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of IRON. China Universal Asset Management Co. Ltd. grew its position in shares of Disc Medicine by 96.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,717 shares of the company's stock valued at $281,000 after purchasing an additional 2,813 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in Disc Medicine by 45.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company's stock valued at $54,000 after acquiring an additional 337 shares during the last quarter. SG Americas Securities LLC raised its stake in Disc Medicine by 19.5% in the third quarter. SG Americas Securities LLC now owns 4,864 shares of the company's stock valued at $239,000 after buying an additional 793 shares during the period. Teachers Retirement System of The State of Kentucky acquired a new stake in shares of Disc Medicine during the 2nd quarter worth about $636,000. Finally, Nantahala Capital Management LLC bought a new stake in shares of Disc Medicine during the second quarter worth approximately $6,760,000. Institutional investors own 83.70% of the company's stock.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.